doi: 10.1161/ATVBAHA.108.168930
© 2008 American Heart Association, Inc.
Editorials |
Myocardin
Dominant Driver of the Smooth Muscle Cell Contractile Phenotype
From the University of Pennsylvania Cardiovascular Institute, Philadelphia.
Correspondence to Michael S. Parmacek, MD, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 9035 Gates Pavilion, 3400 Spruce St., Philadelphia, PA 19104. E-mail Michael.parmacek{at}uphs.upenn.edu
A distinguishing feature of the smooth muscle cell (SMC) lineage is its remarkable plasticity required for maintenance and adaptation of the cardiovascular system. The biological properties of SMCs are ultimately determined by the orchestrated expression of genes encoding contractile and cytoskeletal proteins, intracellular enzymes, and cell surface ligands and receptors (for review see1,2). In the postnatal vasculature, medial SMCs exit the cell cycle and assume a "contractile" phenotype required for regulation of vascular tone.3,4 However, in response to vascular injury, SMCs reenter the cell cycle, downregulate expression of contractile proteins, and assume a "synthetic" phenotype resembling a fibroblast.3,4 The modulation of vascular SMC phenotype has been implicated in the pathogenesis of vascular proliferative syndromes including atherosclerosis, restenosis, pulmonary hypertension, and transplant arteriopathy (for review see5).
See accompanying article on page 1505
Myocardin (Myocd) is a recently discovered SMC-restricted transcriptional coactivator that physically associates with the MADS box transcription factor, SRF, to synergistically activate transcription of genes encoding SMC-restricted cytoskeletal and contractile proteins.6 Forced expression of myocardin transactivates multiple SMC-restricted transcriptional regulatory elements.6–8 Remarkably, forced expression of myocardin in embryonic stem (ES) cells induces expression of multiple endogenous SMC genes including SM22
, SM-MyHC, and SM--actin.7 In response to vascular injury, extrinsic cues and intracellular signals converge on myocardin/SRF complexes ultimately regulating and modulating vascular SMC phenotype (for review see9,10). Mice harboring a null mutation in the myocardin gene survive only to embryonic day (E)10.5 and exhibit obvious defects in the embryonic and extraembryonic vasculature including a block in SMC differentiation.11 In addition, mice in which the Myocd gene was selectively ablated in neural crest-derived SMCs exhibit patent ductus arteriosus (PDA) and neonatal lethality resulting from a cell autonomous block in vascular SMC differentiation.12 Taken together, these data demonstrate that myocardin promotes SMC differentiation and the contractile SMC phenotype.
A recent report from Miano and colleagues challenges accepted lineage relationships that define and distinguish the SMC and skeletal muscle cell lineages.13 Cell lineage fate mapping studies revealed that the Myocd gene is expressed transiently in skeletal muscle progenitor cells located within the dermamyotome of the somite and that skeletal muscle cells arise from these myocardin-expressing skeletal muscle progenitor cells.13 In skeletal muscle progenitors, myocardin functions as a transcriptional repressor inhibiting expression or activity of the bHLH myogenic regulatory factors, myogenin and MyoD. The molecular basis of myocardin-induced transcriptional repression is complex involving both HDAC-regulated transcriptional repression of bHLH myogenic regulatory factors, as well as protein–protein interactions that abolish MyoD binding to DNA and the capacity of MyoD to physically associate with MEF2 and synergistically activate transcription.13 These data raise the intriguing possibility that skeletal muscle cells and a subpopulation of mesodermally-derived smooth muscle cells arise from a common progenitor pool. Consistent with this possibility, clonal analysis in mice revealed that some embryonic aortic SMCs arise from the dermamyotome of somites.14 Alternatively, myocardin may be transiently expressed in skeletal muscle progenitors, but this population of cells may be distinct from some, or all, SMC and pericyte progenitors located within the somite.
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Long and colleagues follow-up and extend the findings in this important study. They now report that adenoviral-mediated expression of myocardin in BC3H1 skeletal muscle cells induces expression of SMC and cardiac genes while suppressing expression of a subset of skeletal muscle genes.15 Ad-Myocd–transduced BC3H1 cells assume a spindle-like morphology and decrease their rate of proliferation, resembling contractile SMCs in the vessel wall. Myocardin-transduced BC3H1 cells exhibit slow rhythmic SMC-like contractions when stimulated with contractile agonists. As such, these data demonstrate that myocardin acts in a dominant fashion inducing not only expression of genes encoding SRF-dependent contractile proteins, but also adoption of contractile properties resembling those observed in bona fide SMCs.
These data raise the intriguing question of whether myocardin functions in a dominant fashion as a "master-regulator" of the SMC lineage in a manner analogous to that of basic helix-loop-helix (bHLH) skeletal myogenic regulatory factors including MyoD (for review see16). However, multiple questions must be addressed before one may reasonably conclude that myocardin acts as a "master-regulator" of the SMC lineage. First, it remains unclear why skeletal muscle progenitors residing in the dermamyotome that express myocardin are not irreversibly driven to the SMC fate. If myocardin autoregulates its own expression,17 what is the molecular basis for extinction of myocardin expression in skeletal muscle progenitor cells? Second, it remains to be determined whether forced expression of myocardin induces nonskeletal muscle cell lines to assume a SMC contractile phenotype. Does overexpression of myocardin in cardiac myocytes cause these cells to transdifferentiate into SMCs? What about nonmuscle cell lineages? Third, unlike bHLH skeletal myogenic regulatory factors, which function by binding directly to cis-acting regulatory elements encoded within the genome, myocardin functions exclusively as a transcriptional coactivator. It is generally believed that transcriptional coactivators evolved primarily to transduce extrinsic stimuli and developmental cues thereby extending and modulating information encoded within the genome required for cellular adaptation (for review see18). Consistent with its role as a transcriptional coactivator, vascular injury induces repression of myocardin-induced activation of SMC-restricted genes thereby modulating vascular SMC phenotype.3,4
Elucidation of the developmental programs that regulate cell fate decisions and differentiation of the smooth muscle cell lineage(s) is fundamentally important at a basic level and relevant to understanding the pathogenesis of common forms of vascular disease. The demonstration that myocardin acts in a dominant fashion repressing the skeletal muscle phenotype and promoting the contractile smooth muscle cell phenotype raises fundamental questions in existing paradigms of muscle cell development.13,15 Recently, human kindreds were identified with familial thoracic aneurysms and dissections (TAAD) caused by mutations in the SM-myosin heavy chain (Myh11) and SM--actin (Acta2) genes, respectively.19,20 Each of these genes is regulated directly by myocardin in the postnatal vasculature confirming that myocardin-regulated transcriptional targets are directly involved in human diseases affecting the cardiovascular system.12 Further study examining the genetic and epigenetic mechanisms that underlie SMC differentiation promises to inform future therapies for common cardiovascular diseases as well as potential regenerative therapies.
 |
Acknowledgments |
|---|
Sources of Funding
This manuscript was supported, in part, from NIH P01-HL075215 and support from the Commonwealth of Pennsylvania.
Disclosures
None.
|
References |
|---|
 Top References |
|---|
1. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84: 767–801.
2. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007; 27: 1248–1258.
3. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall hemostasis: Implications for the pathogenesis of atherosclerosis. Exp Mol Pathol. 1985; 42: 139–162.[CrossRef][Medline] [Order article via Infotrieve]
4. Owens GK, Loeb A, Gordon D, Thompson MM. Expression of smooth muscle-specific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol. 1986; 102: 343–352.
5. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
6. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA, Olson EN. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001; 105: 851–862.[CrossRef][Medline] [Order article via Infotrieve]
7. Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003; 23: 2425–2437.
8. Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res. 2003; 92: 856–864.
9. Parmacek MS. Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ Res. 2007; 100: 633–644.
10. Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006; 20: 1545–1556.
11. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci U S A. 2003.
12. Huang J, Cheng L, Li J, Chen M, Zhou D, Lu MM, Proweller A, Epstein JA, Parmacek MS. Myocardin regulates expression of contractile genes in smooth muscle cells and is required for closure of the ductus arteriosus in mice. J Clin Invest. 2008; 118: 515–525.[Medline] [Order article via Infotrieve]
13. Long X, Creemers EE, Wang DZ, Olson EN, Miano JM. Myocardin is a bifunctional switch for smooth versus skeletal muscle differentiation. Proc Natl Acad Sci U S A. 2007; 104: 16570–16575.
14. Esner M, Meilhac SM, Relaix F, Nicolas JF, Cossu G, Buckingham ME. Smooth muscle of the dorsal aorta shares a common clonal origin with skeletal muscle of the myotome. Development. 2006; 133: 737–749.
15. Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin Is Sufficient for a Smooth Muscle-Like Contractile Phenotype. Arterioscler Thromb Vasc Biol. 2008; 28: 1505–1510.
16. Weintraub H, Dwarki VJ, Verma I, Davis R, Hollenberg S, Snider L, Lassar A, Tapscott SJ. Muscle-specific transcriptional activation by MyoD. Genes Dev. 1991; 5: 1377–1386.
17. Creemers EE, Sutherland LB, McAnally J, Richardson JA, Olson EN. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development. 2006; 133: 4245–4256.
18. Spiegelman BM, Heinrich R. Biological control through regulated transcriptional coactivators. Cell. 2004; 119: 157–167.[CrossRef][Medline] [Order article via Infotrieve]
19. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, Bourgeois S, Estrera AL, Safi HJ, Sparks E, Amor D, Ades L, McConnell V, Willoughby CE, Abuelo D, Willing M, Lewis RA, Kim DH, Scherer S, Tung PP, Ahn C, Buja LM, Raman CS, Shete SS, Milewicz DM. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007; 39: 1488–1493.[CrossRef][Medline] [Order article via Infotrieve]
20. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, Wegman M, Glancy L, Gasc JM, Brunotte F, Bruneval P, Wolf JE, Michel JB, Jeunemaitre X. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006; 38: 343–349.[CrossRef][Medline] [Order article via Infotrieve]
Related Article:
Arterioscler Thromb Vasc Biol 2008 28: 1505-1510.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||